Automated Volumetric Molecular Ultrasound for Breast Cancer Imaging

用于乳腺癌成像的自动体积分子超声

• 批准号: 10226947
• 负责人: BRUCE L DANIEL
• 金额: $ 15.3万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-08-01 至 2024-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10226947
• 关键词: Acoustics; Anatomy; Animal Model; Automobile Driving; Biological Process; Biopsy; Breast; Breast Cancer Detection; Breast Cancer Model; Breast Cancer Treatment; Callback; Cancer Etiology; Cessation of life; Clinic; Clinical; Clinical Trials; Collaborations; Computer software; Contrast Media; Core Biopsy; Data; Data Set; Dependence; Detection; Development; Devices; Diagnosis; Extravasation; Family; Foundations; Frequencies; General Population; Gold; Health Care Costs; Histology; Human; Image; Image Analysis; Imaging technology; Immunohistochemistry; Industrialization; Malignant Neoplasms; Mammary Gland Parenchyma; Mammary Ultrasonography; Mammography; Measures; Medical; Methods; Microbubbles; Modality; Molecular; Molecular Profiling; Monitor; Morphologic artifacts; Nipples; Patients; Phosphotransferases; Physiologic pulse; Psychological Stress; Research; Research Proposals; Resolution; Rest; Scanning; Schedule; Shapes; Signal Transduction; Speed; Stains; System; Technology; Testing; Time; Tissues; Transducers; Transgenic Mice; Translating; Translations; Ultrasonic Transducer; Ultrasonography; United States; Universities; Visualization; Weight; Woman; accurate diagnosis; base; breast cancer diagnosis; breast imaging; breast lesion; cancer imaging; cancer therapy; cancer type; clinical imaging; clinical practice; clinical translation; cost; cost efficient; diagnostic accuracy; experimental study; first-in-human; imager; imaging approach; imaging capabilities; imaging system; improved; malignant breast neoplasm; molecular imaging; neovasculature; next generation; novel; pre-clinical; prospective; receptor; targeted agent; tool; tumor

Breast cancer is the second leading cause of cancer-related deaths in women in the United States. While mammography is the current first line imaging approach, its diagnostic accuracy is very limited in women with dense breast tissue. In those patients, ultrasound is used to supplement mammography for improved breast cancer detection and characterization. However, it often results in false positive findings with multiple unnecessary callbacks, biopsies, associated health care cost, and psychological stress for women. Ultrasound molecular imaging using contrast agents targeted at cancer-associated molecular signatures on the tumor neovasculature, such as kinase domain receptor (KDR), is an emerging strategy that has shown promising results for breast cancer detection and characterization in preclinical animal models as well as in a recent pilot clinical trial performed by our group. However, current limitations include its operator-dependency, limited anatomical coverage, and the lack of an optimized clinical imaging system for wide-spread breast ultrasound molecular imaging. The purpose of this interdisciplinary, academic-industrial collaboration between Stanford University and Siemens Medical Solutions USA, Inc. is to develop, optimize, and clinically test a new operator- independent whole-breast ultrasound imaging system based on a commercially available and widely used automated human breast volume scanner (ABVS), supporting molecular imaging for improved breast cancer imaging in the clinic. We will also develop imaging strategies to mitigate common artifacts encountered in ultrasound molecular imaging of the breast, including spurious contrast signal from tissue signal leakage and acoustic shadowing from the nipple. To assess feasibility and efficacy in the clinic, the new volumetric ultrasound molecular imaging system will then be clinically tested in women with focal breast lesions using histology and KDR staining levels on immunohistochemistry as gold standard. The technology used in this proposal can be integrated on similar other commercial devices beyond the ABVS (in the USA alone, approximately 1600 units are already used in routine clinical practice) and will therefore have immediate impact on the general public.

乳腺癌是美国女性癌症相关死亡的第二大原因。而 乳房X线摄影是目前的一线成像方法，其诊断准确性在患有乳腺癌的女性中非常有限。 致密的乳腺组织在这些患者中，超声用于补充乳房X光检查，以改善乳房 癌症检测和表征。然而，它经常导致假阳性结果， 不必要的回诊、活组织检查、相关的医疗保健费用以及女性的心理压力。超声 使用靶向肿瘤上癌症相关分子标记的造影剂的分子成像 新血管，如激酶域受体（KDR），是一种新兴的策略，已显示出有前途的 在临床前动物模型以及最近的试点中进行乳腺癌检测和表征的结果 我们团队进行的临床试验。然而，目前的局限性包括其运营商的依赖性，有限的 解剖学覆盖范围，以及缺乏用于广泛乳腺超声的优化临床成像系统 分子成像斯坦福大学和斯坦福大学之间的跨学科、学术和工业合作的目的是 西门子医疗解决方案美国公司（Siemens Medical Solutions USA，Inc.）是开发、优化和临床测试一个新的操作员 一种独立的全乳房超声成像系统，基于市售和广泛使用的 自动化人类乳腺体积扫描仪（ABVS），支持分子成像以改善乳腺癌 在临床上成像。我们还将制定成像策略，以减轻常见的伪影， - 乳房的超声分子成像，包括来自组织信号泄漏的伪对比信号， 乳头的声音阴影为了评估临床的可行性和有效性，新的容积超声 分子成像系统，然后将在临床上测试妇女与局灶性乳腺病变使用组织学和 免疫组化上的KDR染色水平作为金标准。该提案中使用的技术可以是 集成在除ABVS之外的类似其他商业设备上（仅在美国，大约1600个单元 已在常规临床实践中使用），因此将对公众产生直接影响。